ARAV

Aravive, Inc. (ARAV) | Rumor.io

Aravive

ARAV

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about ARAV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Jan 18

Aravive, Inc. (ARAV) has been impacted by the company's decision to delist and deregister its stock, leading to a significant drop in share price.
The delisting is scheduled for February 8th, and some investors are expecting the stock to bounce back before then.
The company's planned dissolution was announced in the October meeting, and the delisting is now underway.

Generated by AI

Sentiment

Of the messages about ARAV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% new
Bearish	—	—	—	0% -100

Bullish· Oct 20

$ARAV chart is looking very promising, with a strong potential for a big increase.
The stock's strong buy rating from Zacks and impressive volume suggest a high level of investor interest and potential for further growth.
With a significant increase in volume and a strong trend upward over the past 60 days, $ARAV is positioned for a big run, potentially doubling or reaching $0.25 in the near future.

Bearish· Oct 20

The company's dissolution and significant liabilities ($45 mil in liabilities, $25 mil in assets) may have negative implications for its financial health.
There are concerns about potential short-selling and manipulation of the stock price, with some users accusing the company of controlling buying and dropping the price.
The stock's recent price action is seen as a "pump and dump" scheme, with some users predicting a significant drop in price, including one user who is shorting the stock and waiting for the price to drop.

Generated by AI

Topics

Of the messages about ARAV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	0%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	100%

Analysts· Nov 20

PiperJaffray raised Aravive's price target to $36 from $15, maintaining an overweight rating.
H.C. Wainwright raised Aravive's price target to $31 from $18, reiterating a buy rating.
Wedbush reiterated an outperform rating for Aravive with a price target of $28.

Announcements· Jan 4

Aravive, Inc. (ARAV) has completed enrollment in the global registrational Phase 3 AXLerate-OC trial for Platinum-Resistant Ovarian Cancer.
The AXLerate-OC trial is a registrational Phase 3 trial aimed at evaluating the efficacy and safety of ARIS-01 in patients with Platinum-Resistant Ovarian Cancer.
Completion of enrollment in the AXLerate-OC trial is a significant milestone for Aravive, Inc. as it moves closer to seeking regulatory approval for its lead asset, ARIS-01.

Generated by AI

Community

Of the messages about ARAV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	0%
Newcomers	—	—	—	100%

Regulars· Aug 3

Aravive's Phase 3 AXLerate-OC trial did not meet its primary endpoint, with the company's shares plummeting 70% premarket.
Analysts have downgraded Aravive's stock, with HC Wainwright and William Blair reducing their ratings to Neutral and Market Perform, respectively.
Aravive's shares have hit a 52-week low after the trial's disappointing results, with the company's stock price falling -62.32% in the pre-market.

Newcomers· Aug 30

New traders are discussing the potential for a breakout in ARAV, citing unusual options trading activity and a 14% pre-market price increase.
Some newcomers are focusing on the unusual options trading activity, noting a 322% increase in call options and wondering if it's a sign of a potential buyout or the end of the company.
Others are speculating about a possible buyout, with one user questioning the suspicious volume and another considering a potential entry point to dip into the stock.

Generated by AI

Also Discussed

Investors talking about ARAV also mention

#	Name	Attention
1	KRTX - Karuna Therapeutics, Inc.	——
2	MYOV - Myovant Sciences Ltd.	——
3	ASLN - ASLAN Pharmaceuticals Limited	——
4	AXLA - Axcella Health Inc.	——
5	EBET - EBET, Inc.	——
6	NBSE - NeuBase Therapeutics, Inc.	——
7	MRSN - Mersana Therapeutics, Inc.	——
8	ZVSA - ZyVersa Therapeutics, Inc.	——
9	WRNT - Warrantee Inc. American Depositary Shares	——
10	UPTD - TradeUP Acquisition Corp.	——

Aravive, Inc.

Location

Social

What share of all stock conversation is about ARAV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Jan 18

Aravive, Inc. (ARAV) has been impacted by the company's decision to delist and deregister its stock, leading to a significant drop in share price.
The delisting is scheduled for February 8th, and some investors are expecting the stock to bounce back before then.
The company's planned dissolution was announced in the October meeting, and the delisting is now underway.

Generated by AI

Sentiment

Of the messages about ARAV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% new
Bearish	—	—	—	0% -100

Bullish· Oct 20

$ARAV chart is looking very promising, with a strong potential for a big increase.
The stock's strong buy rating from Zacks and impressive volume suggest a high level of investor interest and potential for further growth.
With a significant increase in volume and a strong trend upward over the past 60 days, $ARAV is positioned for a big run, potentially doubling or reaching $0.25 in the near future.

Bearish· Oct 20

The company's dissolution and significant liabilities ($45 mil in liabilities, $25 mil in assets) may have negative implications for its financial health.
There are concerns about potential short-selling and manipulation of the stock price, with some users accusing the company of controlling buying and dropping the price.
The stock's recent price action is seen as a "pump and dump" scheme, with some users predicting a significant drop in price, including one user who is shorting the stock and waiting for the price to drop.

Generated by AI

Topics

Of the messages about ARAV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	0%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	100%

Analysts· Nov 20

PiperJaffray raised Aravive's price target to $36 from $15, maintaining an overweight rating.
H.C. Wainwright raised Aravive's price target to $31 from $18, reiterating a buy rating.
Wedbush reiterated an outperform rating for Aravive with a price target of $28.

Announcements· Jan 4

Aravive, Inc. (ARAV) has completed enrollment in the global registrational Phase 3 AXLerate-OC trial for Platinum-Resistant Ovarian Cancer.
The AXLerate-OC trial is a registrational Phase 3 trial aimed at evaluating the efficacy and safety of ARIS-01 in patients with Platinum-Resistant Ovarian Cancer.
Completion of enrollment in the AXLerate-OC trial is a significant milestone for Aravive, Inc. as it moves closer to seeking regulatory approval for its lead asset, ARIS-01.

Generated by AI

Community

Of the messages about ARAV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	0%
Newcomers	—	—	—	100%

Regulars· Aug 3

Aravive's Phase 3 AXLerate-OC trial did not meet its primary endpoint, with the company's shares plummeting 70% premarket.
Analysts have downgraded Aravive's stock, with HC Wainwright and William Blair reducing their ratings to Neutral and Market Perform, respectively.
Aravive's shares have hit a 52-week low after the trial's disappointing results, with the company's stock price falling -62.32% in the pre-market.

Newcomers· Aug 30

New traders are discussing the potential for a breakout in ARAV, citing unusual options trading activity and a 14% pre-market price increase.
Some newcomers are focusing on the unusual options trading activity, noting a 322% increase in call options and wondering if it's a sign of a potential buyout or the end of the company.
Others are speculating about a possible buyout, with one user questioning the suspicious volume and another considering a potential entry point to dip into the stock.

Generated by AI

Aravive

Social

Jan 18

Sentiment

Bullish· Oct 20

Bearish· Oct 20

Topics

Analysts· Nov 20

Announcements· Jan 4

Community

Regulars· Aug 3

Newcomers· Aug 30

Also Discussed

Aravive, Inc.

Company Information

Location

Also Discussed

Social

Jan 18

Sentiment

Bullish· Oct 20

Bearish· Oct 20

Topics

Analysts· Nov 20

Announcements· Jan 4

Community

Regulars· Aug 3

Newcomers· Aug 30